Encorafenib plus binimetinib demonstrates favorable efficacy compared with other treatment option for patients with BRAF-mutated melanoma.

Accredited CME from Imedex

This activity features Dr Paul Nghiem sharing emerging data and expert analysis about diagnosis, the emergence of immunotherapy as a viable therapeutic option, and the evolving standard of care for MCC.
Featuring expert analysis by Dr Howard L. Kaufman of the Rutgers Cancer Institute, this activity contextualizes updates to the standard of care, relays the latest developments in immunotherapy, and offers insight into best practices for the incorporation of novel agents in your clinical practice.
Because Merkel cell carcinoma is a rare form of skin cancer that is seen far less frequently than melanoma, many oncologists have never encountered it in their medical practice.

Conferences

Researchers at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, have identified a potential biomarker in patients with stage IV melanoma being treated with the immunotherapy pembrolizumab.

Read More

News

Encorafenib plus binimetinib demonstrates favorable efficacy compared with other treatment option for patients with BRAF-mutated melanoma.
A recent study analyzed the effectiveness of adjuvant vemurafenib in patients with resected, BRAFV600 mutation-positive melanoma
Patients with metastatic melanoma and high body mass index have improved progression-free and overall survival rates compared with patients with normal BMI.
In very elderly patients, less aggressive skin cancers on the face might not always need to be treated, a new study suggests.

Quiz

According to a recent study published in JAMA Dermatology, which of the following factors do NOT contribute to treatment delay in melanoma?

Research in Review

Central nervous system imaging is needed during programmed death 1 (PD-1) inhibitor therapy to monitor incidence, patterns of progression, and outcomes of melanoma brain metastases, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Financial toxicity and excessive financial burden appeared common among melanoma survivors, frequently leading to disease-related distress, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Stage III and IV melanoma may have a profound impact on patients’ distress burden, which requires further intervention strategies, according to research that will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

The treatment of advanced melanoma represents a significant burden to the health system, and differs by insurance type and geographic location, according to the results of a regional analysis.

-----

Related Content

Read More

Resources

The National Comprehensive Cancer Network released updated guidelines for the treatment of basal cell skin cancer, squamous cell skin cancer, and merkel cell carcinoma.
Subscribe to Skin Cancer